TrialSignal
Clinical trial intelligence report
AAREN: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05107388
Status
UNKNOWN
Phase
NA
Sponsor
Centre Hospitalier Universitaire de Besancon
Executive brief
Investment-Ready Snapshot
The purpose of this study is to describe the glycemic profile of postmenopausal women treated with alpelisib plus fulvestrant using a continuous blood sugar monitoring device (FreeStyle Libre Pro) over 14 days
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05107388
Indication
Breast Cancer
Modality
medical device
Target
FreeStyle Libre Pro
Intervention
FreeStyle Libre Pro
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.